Randall W. Burt
YOU?
Author Swipe
Supplementary Table S1 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Endpoint versus baseline comparisons: List of genes differentially regulated at 1.5 fold (includes 2.0 fold). 1. Endpoint v baseline (with all polyps) a. Normal tab i. Drug normal v baseline ii. Placebo normal v baseline b. Polyp tab i. Dr…
Related Article from Diagnosing Lynch Syndrome: More Light at the End of the Tunnel Open
Related Article from Diagnosing Lynch Syndrome: More Light at the End of the Tunnel
Supplementary Tables 2C-E from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype Open
Suppl Table 2C - 27 SSA/P genes with high fold change Suppl Table 2D - 28 SSA/P genes by cross validation Suppl Table 2E - Final 51 SSA/P gene signature
Supplementary Figure S1 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Heat map of RNA expression showing all polyps including those with < 50% tumor purity.
Supplementary Figure S2 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Linear correlation of RNASeq (RPKM value) versus RT-qPCR of each gene transcript represented in Figure 3. Each data point represents a distinct sample used in the experiments described in this manuscript.
Related Article from Diagnosing Lynch Syndrome: More Light at the End of the Tunnel Open
Related Article from Diagnosing Lynch Syndrome: More Light at the End of the Tunnel
Supplementary Figure S1 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Heat map of RNA expression showing all polyps including those with < 50% tumor purity.
Supplementary Table S3 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Ingenuity Pathway Analysis of total RNASeq analysis. List of pathways identified from IPA analysis, whether they are up or down, using data from the 1.5 fold differential expression list.
Data from Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population Open
In current clinical practice, genetic testing to detect Lynch syndrome mutations ideally begins with diagnostic testing of an individual affected with cancer before offering predictive testing to at-risk relatives. An alternative strategy …
Supplementary Methods from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Power calculations for experimental design of RNASeq analysis.
Supplementary Tables 2C-E from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype Open
Suppl Table 2C - 27 SSA/P genes with high fold change Suppl Table 2D - 28 SSA/P genes by cross validation Suppl Table 2E - Final 51 SSA/P gene signature
Appendix from Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population Open
Appendix from Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population
Supplementary Figure S2 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Linear correlation of RNASeq (RPKM value) versus RT-qPCR of each gene transcript represented in Figure 3. Each data point represents a distinct sample used in the experiments described in this manuscript.
Supplementary Table S2 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Endpoint only comparisons 3. Endpoint only comparisons (with all polyps, all 20 samples) a. Drug normal to polyp b. Placebo normal to polyp 4. Endpoint only excluding polyps < 50% tumor purity a. Drug normal to polyp b. Placebo normal to p…
Supplementary Table S4 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Relative reads of Inflammation and Immunity Transcriptome panel on Ion Torrent data sequencer compared with the same genes from RNA sequencing on Illumina HiSeq 2500.
Supplementary Table S2 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Endpoint only comparisons 3. Endpoint only comparisons (with all polyps, all 20 samples) a. Drug normal to polyp b. Placebo normal to polyp 4. Endpoint only excluding polyps < 50% tumor purity a. Drug normal to polyp b. Placebo normal to p…
Supplementary 2B from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype Open
HP gene list
Supplementary Methods from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Power calculations for experimental design of RNASeq analysis.
Supplementary Table 1 from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype Open
Patient Demographics
Data from Diagnosing Lynch Syndrome: More Light at the End of the Tunnel Open
Since the recognition of Lynch syndrome, which confers a high risk of colorectal, uterine, and other cancers, approaches to its diagnosis have included a family history of associated cancers and web-based algorithms. Identification of caus…
Supplementary Table 2 legend from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype Open
Suppl Table 2 legend
Supplementary Figure S3 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
CD56 stained cells.
Supplementary Table 2 legend from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype Open
Suppl Table 2 legend
Data from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
To identify gene expression biomarkers and pathways targeted by sulindac and erlotinib given in a chemoprevention trial with a significant decrease in duodenal polyp burden at 6 months (P Cancer Prev Res; 11(1); 4–15. ©2017 AACR.See relate…
Data from Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population Open
In current clinical practice, genetic testing to detect Lynch syndrome mutations ideally begins with diagnostic testing of an individual affected with cancer before offering predictive testing to at-risk relatives. An alternative strategy …
Supplementary Table S5 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Ingenuity Pathway Analysis of Inflammation and Immunity Transcriptome panel.
Supplementary Figure S3 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
CD56 stained cells.
Supplementary 2B from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype Open
HP gene list
SupplementaryFigures 1-4 from Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype Open
Suppl Fig 1 - Diagram of 2-fold differentially expressed genes in polyps Suppl Fig 2 - Heatmap of differentially expressed genes in uninvolved colon Suppl Fig 3 - Heatmap of microarray data Suppl Fig 4 - qPCR validation
Supplementary Table S4 from Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Open
Relative reads of Inflammation and Immunity Transcriptome panel on Ion Torrent data sequencer compared with the same genes from RNA sequencing on Illumina HiSeq 2500.